{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1265812227", "close" : "1265835627", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}

Send us feedback. Tell us what you think about the new Article Page. Send us feedback

Immucor to Present at the Piper Jaffray 21st Annual Health Care Conference

prnewswire

Related Quotes

SymbolPriceChange
BLUD18.710.00
Chart for Immucor, Inc.
{"s" : "blud","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Press Release Source: Immucor, Inc. On Monday November 23, 2009, 5:23 pm EST

NORCROSS, Ga., Nov. 23 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD - News), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that access to its presentation at the Piper Jaffray 21st Annual Health Care Conference in New York, NY will be available via a live, simultaneous webcast.

The Company's presentation is scheduled for Tuesday, December 1, 2009, at 12:30 p.m. Eastern time. Access to the presentation will be available through the "About Us -- Investor Information" section at www.immucor.com.

For those unable to listen to the live broadcast, a replay of the presentation will be available shortly after its completion and will be archived on Immucor's website for approximately 60 days.

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.

Related Headlines

Related Blog Headlines

Related Message Boards

Sponsored Links

Copyright © 2010 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.